logo
logo
IQVIA Holdings Inc.

IQVIA Holdings Inc.

NYSE•IQV
CEO: Mr. Ari Bousbib
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 2013-05-09
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
連絡先情報
2400 Ellis Road, Durham, NC, 27703, United States
919-998-2000
www.iqvia.com
時価総額
$31.07B
PER (TTM)
22.8
34
配当利回り
--
52週高値
$247.05
52週安値
$134.65
52週レンジ
43%
順位35Top 29.9%
4.6
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.6 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$4.36B+0.00%
直近4四半期の推移

EPS

$3.02+0.00%
直近4四半期の推移

フリーCF

$561.00M+0.00%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth Strong Total revenues reached $11.95B USD for nine months, marking a 4.4% increase over prior year period.
Operating Cash Flow Rises Cash provided by operating activities totaled $1.92B USD for nine months, increasing $88M compared to 2024.
R&D Backlog Expansion Research & Development Solutions contracted backlog grew to $32.4B USD as of September 30, 2025, expecting $8.1B conversion soon.
Debt Issuance Completed Issued $2.0B in 6.250% Senior Notes due 2032 to repay revolving credit borrowings and fund corporate needs.

リスク要因

Net Income Declines Net income attributable to IQVIA Holdings Inc. fell to $846M USD for nine months, down $90M from $936M in 2024.
Segment Profit Pressure Total segment profit decreased $43M USD for nine months, reflecting margin compression across core operational areas.
Increased Cost of Revenues Cost of revenues (excl. D&A) grew 6.6% constant currency for nine months, slightly outpacing revenue growth.
Restructuring Costs Incurred $81M restructuring costs recorded for nine months due to ongoing global streamlining and capacity alignment efforts.

見通し

Share Repurchase Authorization $13.73B total authorization; $1.98B remains available as of September 30, 2025 after $1.03B spent YTD.
Future Revenue Recognition Approximately $34.4B of revenues expected from remaining performance obligations, mostly recognized over the next five years.
Debt Maturity Management Repaid Euro denominated 2.875% Senior Notes due 2025 during the quarter, managing debt maturity profile proactively.
New Tax Disclosure Assessment Assessing impacts of ASU 2023-09 regarding income tax disclosures, effective for annual periods beginning January 1, 2025.

同業比較

売上高 (TTM)

Cardinal Health, Inc.CAH
$244.49B
+10.1%
Humana Inc.HUM
$126.36B
+9.9%
Haleon plcHLN
$21.43B
-2.6%

粗利益率 (最新四半期)

Humana Inc.HUM
100.0%
+0.0pp
BeiGene, Ltd.ONC
86.1%
+3.1pp
Illumina, Inc.ILMN
67.0%
-1.4pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
CAH$51.83B31.2-58.9%15.5%
HLN$49.75B23.89.4%26.6%
ALC$39.81B37.94.8%16.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
4.5%
緩やかな成長
4四半期純利益CAGR
27.3%
収益性の大幅な改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年5月4日
|
EPS:-
|
売上高:-
財務レポート
財務データ
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年10月28日|
    売上高: $4.10B+5.2%
    |
    EPS: $1.94+23.6%
    予想を下回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年7月22日|
    売上高: $4.02B+5.3%
    |
    EPS: $1.55-22.1%
    予想を下回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月6日|
    売上高: $3.83B+2.5%
    |
    EPS: $1.42-10.1%
    予想を下回る
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月13日|
    売上高: $15.41B+2.8%
    |
    EPS: $7.57+2.4%
    予想を下回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年10月31日|
    売上高: $3.90B+4.3%
    |
    EPS: $1.57-5.4%
    予想を下回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年7月22日|
    売上高: $3.81B+2.3%
    |
    EPS: $1.99+23.6%
    予想を下回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月2日|
    売上高: $3.74B+2.3%
    |
    EPS: $1.58+1.3%
    予想を下回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月15日|
    売上高: $14.98B+4.0%
    |
    EPS: $7.39+27.0%
    予想を下回る